A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine.
Nevirapine is the most frequently prescribed drug for patients undergoing highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS in sub-Saharan Africa, where the study was conducted.
“Our findings add to existing limited evidence that efavirenz-based therapies produce a more favorable virological and clinical outcome than nevirapine,” said Jean Nachega, MD, PhD, MPH, lead author of the study and associate scientist with the Bloomberg School’s Department of International Health. “Patients started on nevirapine had an increased risk of virologic failure and death, were significantly less likely than those started on efavirenz to achieve high treatment adherence.”
Nachega, in collaboration with Gary Maartens, MD, FCP, professor of Medicine at University of Cape Town, and several other colleagues from the University of Cape Town in South Africa, examined the records of 2,817 HIV- infected adults currently enrolled in Aid for AIDS, a private-sector employer-subsidized disease management program in Africa. Participants were HAART naïve adults who began nevirapine-based or efavirenz-based therapies between January 1998 and September 2004.
Researchers determined how often patients requested reimbursement for their purchases of nevirapine- or efavirenz-based HAART to estimate adherence to their treatment regimens. They also evaluated patients CD4 counts, viral load changes and mortality, which are measurements that indicate how well a treatment is working. Program participants were in nine countries in Africa with the majority in South Africa.
Current World Health Organization guidelines recommend the use of a non-nucleoside reverse transcriptase inhibitor such as nevirapine or efavirenz in resource limited settings. Nearly 67 percent of countries in sub-Saharan Africa recommend nevirapine-based regimens for first line therapy because it is available at a lower cost and in a variety of generic fixed-dose combination regimens. In contrast, the U.S. Department of Health and Human Services and the International AIDS Society-USA both recommend the use of efavirenz because it has a more favorable toxicity profile and greater efficacy.
“Given the rapid roll-out of antiretroviral programs in Africa and the frequent use of first-line nevirapine-based HAART in such programs the assumption that efavirenz and nevirapine are equally effective needs to be reassessed,” said Nachega, who is also professor and director of the Centre for Infectious Diseases at Stellenbosch University in South Africa. “Based on our results, there is a critical need for a large randomized clinical trial to definitively compare the outcomes of efavirenz and nevirapine and for acceleration of efforts to develop lower cost formulations of efavirenz, including generic, fixed-dose combinations in Africa.”
“Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults” was written by Jean B. Nachega, Michael Hislop, David W. Dowdy, Joel E. Gallant, Richard E. Chaisson, Leon Regensberg and Gary Maartens.
The researchers were funded by grants from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health (NIH) and the NIH Medical Scientist Training Program.
The study is published in the October 18, 2008 issue of the journal AIDS.
The above post is reprinted from materials provided by Johns Hopkins University Bloomberg School of Public Health. Note: Content may be edited for style and length.
Cite This Page: